- Natural product: Cannabis (Cannabis sativa)
- Associated study: Predicting the Potential for Cannabinoids to Precipitate Pharmacokinetic Drug Interactions via Reversible Inhibition or Inactivation of Major Cytochromes P450
In Vitro Enzyme Inhibition Experiment
CBD Inhibition on CYP2C19
Inhibition was detected. Cutoff used —
CBD was predicted to precipitate strong drug interactions (AUCR greater than or equal to 5) mediated by CYP2C9, 2C19, and 3A and moderate drug interactions (AUCR between 1.2 and 5) mediated by CYP1A2 and 2D6 based on the AUCR cutoffs recommended by the FDA (https://www.fda.gov/media/134582/ download).
Table 1 lists the oral and inhalational doses and estimated maximum plasma concentrations of CBD, THC, and THC metabolites used for predicting the magnitude of pharmacokinetic cannabinoid-drug interactions.
- CYP2C19 4311137
Cell fraction Pooled human liver microsomes -7999662
Results
| Sample | Compound measured | Value | Measurement | Study sequence | Additional information | N replicates |
|---|
Experimental Conditions
0.1 mg/ml
Commercially available
10 µM